announced on the 6th that it expects the Corona 19 pneumonia treatment “Nusepin” developed on the basis of inflammatory complex inhibitor technology will be able to reduce the severity and mortality rate of Corona 19 reproliferation.
Chaperon is paying attention to the situation where new mutations are spreading, such as the recent positive rate of Corona 19 among inbound travelers from China which reached 31.5%. In the case of reinfected patients, there are also research findings that hospitalization and mortality increase compared to the first infection.
When infected with the COVID-19 virus, cytokines are released as a defense mechanism. Moderate to severe corona patients may experience a “cytokine storm,” an overactive immune response. He said this can lead to systemic organ failure where organs are damaged.
Nusepin, which is in multinational Phase 2b and 3 clinical trials, is an anti-inflammatory treatment that suppresses cytokine storms. Currently, approximately 70% of patients are recruited from 6 countries worldwide. The upside is that it doesn’t kill the virus, but is rather a treatment for pneumonia caused by an overactive immune response. The treatment effect is said not to be significantly affected by viral mutations.
As soon as phase 2b is completed, Chaperon plans to seek conditional approval from domestic and overseas licensing agencies. A Chaperon official said, “There is no effective pneumonia treatment that can be widely used for various Corona 19 mutations,” and “we expect emergency use approval to be possible.”
Reporter Han Min-soo hms@hankyung.com
